Showing 1 - 3 results of 3 for search 'F. B. Askeland', query time: 0.03s Refine Results
  1. 1
    P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

    P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY by F. B. Askeland, E. Haukås, T. S. Slørdahl, D. Schjøll, A. Lysen, E. Hermansen, F. Schjesvold

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE

    P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE by T. S. Slørdahl, F. B. Askeland, M. S. S. Hanssen, S. M. Sundt-Hansen, N. T. Vethe, H. Hjorth-Hansen, M. H. Fenstad, A. Waage, Ø. Hjertner, F. Schjesvold, A. Sundan

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)

    P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT) by F. B. Askeland, A.-M. Rasmussen, A. Lysen, E. Haukås, A. Eilertsen, M. Moksnes, G. Tsykunova, A. Vik, B. D. Eiken, J. H. Sørbø, J. Rolke, K. O. Sand, R. F. Hallstensen, L. Myrseth, T. S. Slørdahl, F. Schjesvold

    Published 2022-06-01
    Get full text
    Article

Search Tools: